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MutantsIntegrase (IN) is the enzyme responsible for the integration of the retroviral genome into the host cell DNA.
Herein, three mutants of conserved residues (V79, S85 and I146) of the central core domain (CCD) of an
Avian Sarcoma/Leukemia Virus IN were analyzed in vitro. Our data revealed (i) the inability of S85T mutant
to form dimers and tetramers in the absence of DNA and (ii) a slightly reduced ability of V79A IN in tetramers
formation. Surprisingly, both mutants were still able to efﬁciently achieve concerted DNA integration. This
could be explained by the ability of the two mutants to form complexes in the presence of DNA. These
data suggest a strong structural role of the region encompassing V79 and S85 residues (β2/β3 turn-β3
strands) following binding to viral DNA and highlight the dynamic nature of IN.et Pathologie Comparée, UMS
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Integration of genetic material into the host cell genome is common
to all retroviruses and is indispensable for a productive retroviral infec-
tion (Engelman, 2010). Following retrovirus entry into the cell, the viral
RNA genome is reversely transcribed into a double-stranded linear DNA
in the cytoplasm. The resulting DNAmolecule is actively transported to
the nucleus as a component of the pre-integration complex (PIC), and
serves as an immediate precursor for the integration reaction. The inte-
gration process can be subdivided into three steps. Firstly, during the
initial 3′-processing step (which proceeds in the cytoplasm), the two
3′-terminal nucleotides of each viral end are cleaved to create the char-
acteristic CA\OH 3′-ends, with a two-bases 5′ overhang. Secondly,
during the strand transfer reaction (that proceeds in the nucleus), the
3′-hydroxyl ends of the viral DNA attack the phosphodiester bond in
each strand of the cellular DNA at cleavage sites separated by
4–6 base pairs, depending on the retrovirus (Engelman, 2010). Finally,
during the gap ﬁlling step, the 5′-overhanging dinucleotides of the
viral DNA ends are removed and single-strandedDNAgaps are repaired,creating a short duplication of host sequence. The size of the duplication
is 4 to 6 bp; however, examples of size variations have been reported
(Moreau et al., 2000). The 3′-processing and strand transfer steps are
catalyzed by the viral integrase (IN) enzyme whereas the repair of
DNA gaps most probably involves cellular enzymes (Espeseth et al.,
2011; Smith and Daniel, 2006). The integration process is termed “con-
certed” because it allows the coupled integration of a pair of viral ends
at the same site (within 4–6 bp) of the host DNA.
Only two viral elements i.e. the IN protein and speciﬁc sequences
at the ends, known as att (attachment) sequences are required for
integration. A number of cellular proteins have been identiﬁed as
binding partners for the IN of Avian Sarcoma/Leukemia viruses
(ASLV) (Andrake et al., 2008; Greger et al., 2005), Moloney Murine
Leukemia virus (Studamire and Goff, 2008) and Human Immunodeﬁ-
ciency Virus type 1 (HIV-1) (Al-Mawsawi and Neamati, 2007; Van
Maele et al., 2006). Among them, the lens epithelium-derived growth
factor (LEDGF/p75) is a critical factor that acts as a chromosomal recep-
tor that tethers lentiviral IN and viral DNA to host DNA (Meehan and
Poeschla, 2010).
The IN enzyme consists of three domains, the N-terminal domain
(NTD), the central core domain (CCD) and the C-terminal domain
(CTD); all are necessary for its activities (Engelman et al., 1993; van
Gent et al., 1993). The CCD is the most conserved domain (Bujacz et
al., 1995). It contains a highly conservedmotif composed of two aspartic
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arated from glutamic acid by 35 residues. This D,D(35)E motif consti-
tutes the active site of the protein and has been shown to bind
catalytic metal cations (Mg2+, Mn2+) (Bujacz et al., 1996). The CCD
is involved in recognizing viral ends (Esposito and Craigie, 1998; Jenkins
et al., 1997), binding to host DNA and inﬂuences the choice of the inte-
gration site (Diamond and Bushman, 2005; Konsavage et al., 2007). In
the CCD, an active-site loop (144–153 in ASLV IN; 141–149 in HIV-1
IN) is found in close proximity to the catalytic site in the structures
(Esposito and Craigie, 1998; Heuer and Brown, 1997).
The formation of multimeric molecules is essential to correct IN
function, as shown by trans-complementation experiments in vitro
(Engelman et al., 1993; van Gent et al., 1993) and in vivo (Fletcher et
al., 1997). Most data accumulated recently suggest that the IN complex
functions as a tetramer (Faure et al., 2005; Hare et al., 2009a, 2009b,
2010; Kotova et al., 2010; Li et al., 2006; Maertens et al., 2003, 2010;
Michel et al., 2009).
Structures of fragments of IN from several different viral sources
were solved by either crystallography or solution NMR methods (see
Jaskolski et al., 2009 for review). Among them, single or double-domain
structures of ASLV INs were published (Bujacz et al., 1995, 1996, 1997;
Lubkowski et al., 1998a, 1998b, 1999; Yang et al., 2000). We have
recently determined a new structure of the CCD of RAV-1 to 1.8 Å reso-
lution which exhibited an unexpected new dimeric arrangement
(Ballandras et al., 2011). Structures and images of the full-length IN
complex were available only recently. At ﬁrst, a particle image recon-
struction by electronic microscopy of a tetramer of HIV-1 IN bound to
DNA, at 27 Å resolution was published (Ren et al., 2007). After that,
3D models of negatively stained full-length HIV-1 IN, alone or com-
plexed with the cellular cofactor LEDGF/p75 and either viral or cellular
DNA, were proposed by electron microscopy (Michel et al., 2009). Last
year, the crystal structure of the full-length IN from Prototype Foamy
Virus (PFV) complexed with its cognate viral DNA (Hare et al., 2010)
and with both viral and target DNA (Maertens et al., 2010) was deter-
mined. These structures led the authors to propose a model for the
HIV-1 intasome (i.e. the minimal DNA-IN functional IN complex) as-
sembled using the PFV structure as template (Krishnan et al., 2010).
The architecture of the PFV intasome was markedly different from all
previously reported models and the dimer–dimer interface stabilized
by intermolecular NTD–CTD interactions. Finally, the use of small
X-ray scattering (SAXS) and biochemical cross-linking analyses coupled
with mass spectrometry showed that the full-length ASLV IN dimer in
solution resembled that of the DNA-binding “inner” domain of the
PFV intasome (Bojja et al., 2011). Altogether, these recent data suggest
that the association of the intasomemay be different from all previously
reported models.
IN mutants provide valuable tools both for deciphering the integra-
tion reaction and for further studying themultimeric complex.We pre-
viously introduced 30 single amino acid substitutions into an Avian
Leukemia Virus named Rous-Associated Virus type 1 (RAV-1) IN and
analyzed 3′-processing, strand transfer, and disintegration activities,
aswell as theDNA binding properties, of the resultingmutants (Moreau
et al., 2002, 2003, 2004). In the present work, we chose three IN mu-
tants carrying mutations on residues which are well-conserved in INs
of retroviruses and retrotransposons (V79A, S85T and I146A) (Bujacz
et al., 1995; Moreau et al., 2002). We examined the activities of these
mutants on concerted DNA integration as well as the oligomeric status
of the resulting proteins. Our data suggest an important structural role
of the DNA in the formation of the oligomers.
Results
Structure-based description and activities features of the mutants
The NTD, CCD and CTD of RAV-1 IN encompass residues 1–50,
51–207 and 208–286 respectively (Fig. 1A). Residues Val-79, Ser-85and Ile-146 in the CCD are conserved residues among retroviruses and
retrotransposons INs (Bujacz et al., 1995; Moreau et al., 2002) (Fig. 1A).
Although no structural data for the full-length Rous-Associated Virus
type 1 (RAV-1) IN is currently available, a dimeric structure containing
the CCD–CTD of Rous Sarcoma Virus (RSV) IN has been determined at
2.5 Å resolution (PDB 1C0M) (Yang et al., 2000). The CCD consists of a
ﬁve-stranded mixed β-sheet ﬂanked by ﬁve α-helices and the two
CCDs are related by a 2-fold symmetry axis in 1C0M, whereas the CTDs
have a similar fold but associate in an asymmetric manner (Bujacz et
al., 1995; Yang et al., 2000). RAV-1 IN has a 98% sequence identity with
RSV IN and the 1C0M structure was used as the best model (Table 1).
The crystal structure of PFV IN in complex with viral and target DNAs is
known (Maertens et al., 2010). RAV-1 and PFV INs show a limited se-
quence identity of 15% on the entire protein and 23% on the CCD. Conse-
quently, the CCDswere superimposedwith an rmsd of 2.3 Å between Cα
pairs and the macromolecular structure of PFV IN and DNAs was used as
additional structural support in the study of RAV-1 IN mutants.
The Val-79 residue is a buried residue which belongs to the β2
strand of the CCD in RSV IN (Fig. 1B). The main-chain carbonyl and
the amide groups of Val-79 are hydrogen-bonded with those of the cat-
alytic Asp-64 of strand β1 (catalytic residue, close-up view of Fig. 1B).
Furthermore, the side-chain of Val-79 makes a van der Waals contact
with that of residue Asp-64 (Table 1). Residue Val-79 corresponds to
Val-144 in PFV IN, which side chain is also involved in a similar contact
with the catalytic residue Asp-128. The hydrogen bonding pattern
should be kept in the V79A mutant, whereas the contact between side
chains of Ala-79 and Asp-64 should be lost (Table 1). Val-79 residue
also has contacts with residue Ile-88 and Asn-160. The V79A mutation
does not remove these contacts (Table 1). In contrast, contacts between
residue Val-79 and surrounding residues Thr-66, Val-156, Leu-163 are
also apparently lost in the mutant. Thus, the V79A substitution can
have a direct effect on the conformation of Asp-64 and the activity of
IN, as reﬂected by the reduction of the 3′ processing activity (30–60%)
(Moreau et al., 2002).
The Ser-85 residue is held in a tight β-turn which separates the β2
and β3 strands of the CCD (Fig. 1B). Its hydroxyl group stabilizes this
turn by interacting with the main-chain amide of Ala-87 (Table 1). It is
also hydrogen bonded to the imidazole ring of His-212 (Table 1 and
close-up view of Fig. 1B) which belongs to the α6 helix connecting the
CCD to the CTD. Residue Ser-85 corresponds to Thr-150 in PFV IN,
which determines a van derWaals contact with Leu-269. This last corre-
sponds to residue His-212 in RAV-1 IN and is equally part of theα6 helix.
α6 is considered to be a hotspot in retroviral INs, because it could orien-
tate the CTDwith respect to the CCDduring the integration process (Yang
et al., 2000). The structural features of RAV-1 IN might be conserved in
the S85T mutant as suggested by our 1C0M-based model (Table 1).
However, the deﬁciency of S85T in DNA binding (Moreau et al., 2002)
suggests that the S85T structure differs from that of the wild type.
Ile-146 is a highly conserved residue located on the active-site loop
(Acevedo et al., 2010). This loop is well ordered in 1C0M, the two-
domain CCD–CTD structure of RSV IN (Yang et al., 2000). There, the
side-chain of Ile-146 is exposed to the solvent and its main-chain is
close to the fundamental Asp-121 of the catalytic site (Fig. 1B). Ile-146
residue has van der Waals contacts with residue Asn-122, Pro-147
and Ser-150 (Table 1). The I146A mutation removes the contacts with
Ser-150 and Asn-122 (Table 1). Interestingly, residue Ile-146 corre-
sponds to Thr-210 in PFV IN,within the active-site loop (PFV IN residues
211–220)which is involved in separating viral DNA strands in the vicin-
ity of the active site (Hare et al., 2010).
V79A, S85T and I146A have been characterized previously for their
3′-processing, strand transfer and disintegration activities using oligo-
nucleotides thatmimic the ﬁnal 15 bp of the att sequence and compared
with activities of thewild-type protein (Moreau et al., 2002). The level of
3′-processing activity of the V79A, S85T and I146Amutants was slightly
reduced (30–60%) comparatively to that of theWT IN. The strand trans-
fer activities of V79A and S85Twere 60–90% to that of theWTwhile the
Fig. 1. Description of the IN mutants analyzed. (A). Structure-based sequence alignment between RAV-1 IN (personal sequence (GenBank ID: JF514545)) and HIV-1 IN (Uniprot
P04585). Identities are written in white on a red background; similarities are written in red and boxed in blue. Secondary structural elements presented on the top of the aligned
sequences have been calculated from the CCD–CTD structure of RSV IN (PDB 1C0M) using the program DSSP (Kabsch and Sander, 1983). Secondary structure elements presented on
the bottom have been calculated from the NTD–CCD and the CCD–CTD structures of HIV-1 IN (PDB 1K6Y and 1EX4). Secondary structure elements observed in the NTD, CCD and
CTD are colored in blue, green and red respectively. Helices, strands and turns are represented by squiggles, arrows and TT letters respectively. Green triangles on top of the aligned
sequences mark the three studied mutations V79A, S85T and I146A in RAV-1 IN. Red stars show the invariant catalytic residues (DDE) of INs. The ﬁgure was drawn with ESPript
(Gouet et al., 2003). (B). Ribbon representation of the dimeric CCD–CTD structure of RSV IN (PDB code 1C0M). The ribbon is color-ramped from the N-terminal part (blue) to
the C-terminal (red) in the proximal monomer B. Mutation sites (green sticks) and catalytic residues (red sticks) are indicated. The three close-up views on the right hand side
highlight important intramolecular contacts in the mutation sites Ser-85, Ile-146 and Val-79. Hydrogen-bonds are shown by a dashed line. Figure was created with PyMOL (DeLano,
2002).
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(N90%). Disintegration activities of all three mutants were also close to
that of the wild-type protein (60–90% for S85T and N90% for V79A and
I146A). The mutants were also tested for their ability to bind a small
DNA substrate containing the att sequence. The viral DNA binding efﬁ-
ciency of I146A was similar to that of the wild type IN whereas that of
the S85Tmutant was reduced to 42% of thewild type protein IN. A slightdecrease of 20% in DNA binding efﬁciency was also observed with the
V79A mutant (Moreau et al., 2002).
Effects of IN mutations on concerted DNA integration
The INmutantswere analyzed for their ability to perform two-ended
concerted DNA integration using a reconstituted in vitro assay (Fig. 2).
Table 1
List of intramolecular contacts between side-chains in RAV-1 IN mutations sites. Con-
tacts are for monomers A and B. No intermolecular contact was observed in these
sites. Maximum contact distance between side-chains is 4 Å, residues in italic show
contact distances b3.2 Å.
V79 (A, B) 1C0M structure 1C0M-based model of V79A
Contacts D64(B) T66(B) I88(B) V156(A,B)
N160(A,B) L163(A,B)
I88(B) N160(A,B)
S85 (A, B) 1C0M structure 1C0M-based model of S85T
Contacts D82(A,B) A87(A,B) H212(A,B) D82(A,B) A87(A,B) H212(A,B)
I146 (A, B) 1C0M structure 1C0M-based model of I146A
Contacts N122(B) P147(A,B) S150(A) P147(A,B)
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described for ASLV by others (Aiyar et al., 1996; Chiu and Grandgenett,
2000, 2003; Grandgenett et al., 2009; Hindmarsh et al., 1999, 2001;
Vora et al., 2004; Vora and Grandgenett, 2001) and by us (Moreau et
al., 2003, 2004, 2009) as well as for HIV-1, Simian Immunodeﬁciency
Virus (SIV) and PFV. Brieﬂy, the system is composed of a linear donor
DNA (D), a plasmid acceptor DNA, and recombinant IN. A donor DNA
of 326 bp containing 15 bp of the terminal U3 att sequence at one end
and 12 bp of the U5 att sequence at the other end (Fig. 2A) (Moreau et
al., 2003, 2004) was used in this study. Products of the integration reac-
tion can arise from concerted or non-concerted integration DNA pro-
cesses (Fig. 2B). Concerted integration products include those thatA
B
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INTE
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AATGTAGTCTTATAC
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Fig. 2. Principle of the in vitro concertedDNA integration assay. (A). Representation of the dono
dinucleotides are underlined. The closed rectangle represents the supF tRNA transcription unit.
the donor DNA (D), target plasmid and puriﬁed IN protein (Moreau et al., 2003, 2004). Concerte
single donor (circular full-site integration product (cFS)) and those that result from integration
site integration product (linFS)). Non-concerted integration products result from one-ended in
tegration of two donor DNAs (multiple half-site integration product (mHS)) and from integrati
product (cHS)). Auto-integrants result from integration of donor DNA into a second donor DNresult (i) from two-ended integration of both viral ends from a single
donor at the same integration site (generating a circular product
named circular full-site (cFS)) or (ii) from two one-ended integrations
of two viral ends from two donors at the same integration site (generat-
ing a linear product (linear full-site (lin FS))). Non-concerted integration
products result from one-ended donor integration of either a single
donor (named half-site integration product (HS)) or of two or more do-
nors at different sites on the acceptor DNA (multiple half-site products
(mHS)). Other products resulting from two-ended integration of a single
donor with insertion at different sites on the acceptor DNA (cHS) are
also observed (Moreau et al., 2003, 2004). Autointegration products,
which result from integration of one donor DNA into a second donor
DNA, are also generated (D–D product).
The in vitro integration products were analyzed in two ways. In
the ﬁrst assay, radiolabeled donor DNA was used and the integra-
tion products were separated on agarose gel and visualized by auto-
radiography. No integration products was observed when IN was
absent (data not shown; refer to Moreau et al., 2003, 2009). By con-
trast, three characteristic mixes of bands were revealed with the
WT IN (Fig. 3A, lane 1). The slowest migrating bands corresponded
to a mix of circular forms (cFS, HS, cHS and mHS), the middle band
corresponded to the linear linFS product, and the fastest migrating
band corresponded to D–D autointegration products, as previously
described (Moreau et al., 2003, 2004). The integration efﬁciency of
each mutant was determined on gel by quantifying the intensity
of bands corresponding to cFS, HS, cHS, mHS and linFS and in
comparison to that of the wild-type protein (Fig. 3B, black bars).target DNA
GRATION
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(B). In vitro assay. Schematic representation of the reconstituted integration reactionwith
d integration products include those that result from integration of both viral ends from a
of two viral ends from two donors at the same integration site (generating the linear full-
tegration of a single donor DNA (half-site integration product (HS)), from one-ended in-
on of two viral ends from one donor at two different sites (generating the circular Half-Site
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Fig. 3. Analysis of the integration products. (A). Integration reactions performedwithwild type IN andmutantswere analyzed by gel electrophoresis and visualized by autoradiography as
previously described (Moreau et al., 2003, 2004, 2009). Schematized integration products are shown on the right (B). Quantiﬁcation of integration products shown in (A), corresponding
to linFS+cFS+HS+cHS+mHS integration products (black bars) and total number of colonies recovered after the reaction products were introduced into MC1061/P3 bacteria (white
bars). Integration efﬁciency of the wild-type protein was set as 100%. The experiment was repeated at least three times and the standard deviation is indicated.
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cantly reduced the whole integration efﬁciency (11% and 7% that
of the wild-type IN, respectively) (lanes 2 and 3). Mutant I146A dis-
played lower integration efﬁciency than the wild-type protein (52%)
(lane 4).
In the second assay, the integration products were directly used
to transform MC1061/P3 E. coli bacteria. These bacteria contain
drug-resistance markers with amber mutations. Only DNA products
carrying the amber mutation suppressor gene (supF) should be able
to replicate and form colonies under drug selection. Among the
different integration products, one-ended (HS) and multiple one-
ended donor integration products (mHS) and the linear products
(linFS) are lost. Only circular two-ended forms of the integration
products (cFS and cHS) are able to replicate (after repair of the
gaps and overhangs in bacteria). Thus, the efﬁciency of IN proteins
to mediate the two-ended integration process, whether concerted
(cFS) or not (cHS), can be estimated by cloning analysis. Thus, the
two-ended integration efﬁciency of each mutant was determined
from the number of clones obtained in relation to the number of
clones obtained with the wild type protein. Between 98 and 324
resistant colonies were obtained according to the experiment with
the wild-type IN. The mutations of residue I146 drastically reduced
the two-ended integration process (to 25% that of the wild type
IN) (Fig. 3B; white bars). In contrast, the efﬁciency of the S85Tmutant
for two-ended donor integration was slightly reduced (80%) compared
to that of the wild type IN. That of the V79A mutant was even less
efﬁcient (47% of the efﬁciency of the wild-type IN) (Fig. 3B).
The difference in clones number between WT and S85T INs is not
signiﬁcant (Student test p=0.81) but the difference between WT IN
and V79A or I146A INs is signiﬁcant (p=0.0079 and pb0.0001,
respectively).Cloning and sequencing of integration products
The previous data suggest that mutants V79A and S85T are per-
turbed for overall integration activity (as determined by gel electropho-
resis), but are still particularly adapted in two-ended concerted
integration (as determined by bacterial transformation efﬁciency). To
check the accuracy of integration performed by both mutants, several
clones were picked up and the donor DNA–acceptor plasmid junctions
of isolated integration products were sequenced. We could therefore
discriminate between concerted (cFS) and non-concerted (cHS) inte-
gration products. With WT IN, eighteen clones were ampliﬁed and
sequenced at the donor–target DNA junctions (Table 2). Eight clones
exhibited a characteristic duplication of 6 bp of target DNA and ﬁve
clones a duplication of other size (Table 2) that is 13 clones were of
type cFS. Five clones (of type cHS), exhibited a deletion of target DNA
at the integration sites varying from 317 to 1398 bp in size. Thus,
most of the two-ended integration products obtained with the U3–U5
donor DNA and ampliﬁed in bacteria (13/18 i.e. 72.2%) (Table 2)
resulted from a two-ended and concerted DNA integration event.
With V79A and S85T INs, seventeen clones were sequences. 88.2% and
82.3% of clones generated by V79A and S85T INs were the result of a
concerted integration process, respectively. The difference in clones
number between each IN and another is not signiﬁcant (Fisher's test
p=0.56). Therefore, both V79A and S85T INs were able to integrate
the U3–U5 donor by an accurate two-ended concerted integration pro-
cess as the WT IN.
Effects of IN mutations on IN oligomerization
ASLV and HIV INs are present as mono-, di-, and tetramers in
solution, as shown by size exclusion chromatography, analytical
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Fig. 5. Protein–protein cross-linking of IN mutants in presence of DNA substrates.
1.5 μg of IN proteins (45 pmol) were incubated overnight at 4 °C without (lane 1) or
in presence of different DNAs substrates (0.6 pmol): the D donor DNA (lane 2), the
D2 (pU3–ΔU5 (Moreau et al., 2009)) donor DNA (lane 3), the D+target DNAs (lane
4), the D2+target DNAs (lane 5) and the target DNA alone (line 6). Reactions products
were then analyzed as in Fig. 4. (A). V79A IN. (B). S85T IN. Here is shown a represen-
tative gel experiment.
Table 2
Sequencing of donor–target junctions from clones obtained with the different INs.
Target DNA at the integration site IN
WT V79A S85T
Duplication of 6 bp a 8 9 8
Other size of duplication (2–7 bp) a 5 6 6
Deletion b 5 2 3
Total number of clones 18 17 17
Percent of clones that are concerted c 72.2 88.2 82.3
a After cloning integration reaction products into MC1061/P3 E. coli bacteria, several
integration products were ampliﬁed and sequenced. Both donor–target DNA junctions
were sequenced. The duplication of a short sequence of target DNA is the mark of a
two-ended and concerted DNA integration process (having generated clones of type
cFS).
b A deletion of target DNA is the mark of a two-ended and non-concerted DNA inte-
gration process (having generated clones of type cHS). Deletions range from 317 to
1398 bp, 133 to 170 bp, and 254 to 1969 bp for WT, V79A and S85T INs, respectively.
c Number of clones with a duplication of target sequences divided by total number of
clones×100.
47J. Charmetant et al. / Virology 421 (2011) 42–50ultracentrifugation, and cross-linking (Andrake and Skalka, 1995; Bao
et al., 2003; Coleman et al., 1999; Jones et al., 1992; Moreau et al.,
2003, 2004). The three mutants were tested for their ability to form
a complex by protein–protein cross-linking. In this experiment, the
proteins were incubated with the Bis SulfoSuccinimidyl Suberate
cross-linker (BS3) and the reaction products were analyzed on SDS
PAGE and revealed by silver staining.With wild-type IN and in the ab-
sence of the cross-linker, only the monomeric form of IN was ob-
served (Fig. 4, lane 1). In the presence of BS3, products with the
expected molecular weights of IN monomers, dimers and tetramers
as well as higher-order oligomeric forms (at the top of gel) were ob-
served (Fig. 4, lane 2). Dimers were the main IN form. V79A IN was
revealed as monomeric and dimeric complexes and a faint signal indi-
cated that the proportion of tetrameric forms was reduced (Figs. 4,
lane 3 and 5, lane 1). In contrast, the S85T protein was not cross-
linked by BS3 and only the monomeric form and a few dimers were
observed on gel (Fig. 4, lane 4). I146A mutant was revealed as mono-
meric, dimeric and tetrameric complexes but a fainter signal indicat-
ed that the proportion of tetrameric forms may be slightly reduced
(lane 5).
DNA-induced association of V79A and S85T INs
Our results showed that two-ended DNA integration remained efﬁ-
cient (47% and 80% that of the WT IN for V79A and S85T, respectively)M WT  WT V79A S85T I146A
monomer
dimer
tetramer150
100
75
50
37
KDa
-
BS
3
+ BS3
1 2 3 4  5
Fig. 4. Protein–protein cross-linking ofwild type IN andmutants. Proteinswere incubated
in the presence of BS3. Reaction products were analyzed on an 8% SDS polyacrylamide gel
and revealed by silver staining. The migrations of monomers, dimers and tetramers are
marked.−BS3: without BS3. M: mass marker with sizes (in kDa).(Fig. 3) despite the observation that S85T and V79A were impaired in
dimer/tetramer and tetramers formation, respectively. It was previous-
ly observed that the assembly of the ASLV tetramer was induced upon
interaction with a “disintegration” substrate, which represented a
viral-host DNA integration intermediate (Bao et al., 2003). The oligo-
meric state of HIV-1 IN could also be affected by the presence of DNA
(Deprez et al., 2001; Faure et al., 2005; Vercammen et al., 2002). Assum-
ing that two-ended concerted integration is carried out by a tetramer
(Faure et al., 2005; Hare et al., 2009a, 2009b, 2010; Kotova et al.,
2010; Li et al., 2006; Maertens et al., 2003, 2010; Michel et al., 2009),
our data could be explained by considering a role of viral DNA in assem-
bling catalytically active V79A and S85T IN complexes. Thus, we used
the crosslink approach to analyze the oligomeric forms of WT IN,
V79A and S85T INs after binding to different DNA substrates: the U3–
U5 (D) donor DNA, the D2 substrate (corresponding to pseudoU3–ΔU5
(Moreau et al., 2009) inwhichU3was replaced by amutated U3 and U5
was deleted) and the target DNA. IN proteinsweremixedwith donor or
target DNAs or both and were incubated overnight at 4 °C before being
cross-linked with the BS3. For WT IN, the addition of DNA did not
change the equilibrium between monomers, dimers and tetramers
(data not shown). In the absence of DNA, V79A IN exists in the solution
in equilibrium between monomer and dimers (Figs. 4, lane 3 and 5A,
lane 1). Addition of the U3–U5 donor DNA (lane 2), the D2 donor
(lane 3), the target DNA (lane 6), the D+target DNA (lane 4), or the
D2+target DNA (lane 5) enhanced its oligomerization. Products with
the expected molecular weights of IN tetramers as well as higher-
order oligomeric forms were observed on the gel (Fig. 5A, lane 2 to 6).
These results clearly indicate that binding of DNA (viral or not) induces
V79A IN oligomerization. In the absence of DNA, S85T IN exists in the
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The incubation of S85Twith DNA reproducibly led to a slight increase in
the formation of dimeric forms (Fig. 5B, lanes 2 to 6), but the effect is
less strong than the effect of DNA on enhancing the formation of higher
oligomers of V79A.Discussion
The CCD domain of retrovirus INs have several features in common:
(i) it contains a catalytic site formed by three acidic residues arranged in
a highly conserved D,D(35)E and this motif has been shown to bind
catalytic metal cations; (ii) it contains an active-site loop in the 35 res-
idues spacer and (iii) it consists of a ﬁve-stranded mixed β-sheet
ﬂanked by ﬁve/six α-helices.
Within the CCD, the active-site loop (144–153 in ASLV IN; 141–149
in HIV-1 IN; 211–220 in PFV IN) is found in close proximity to the cata-
lytic site in the structures. This loop may achieve a ﬁxed conformation
when a DNA substrate (Yang et al., 2000) or an IN inhibitor (Lubkowski
et al., 1998b) is bound. This loop is involved in viral DNA binding in the
tetrameric models of HIV IN (Michel et al., 2009) and in the PFV inta-
some structure (Maertens et al., 2010). In the Rous Sarcoma Virus
(RSV) IN, mutations were designed to alter the length the loop: most
of the mutants had enzymatic activity in the presence of Mn2+ but
were inactivewithMg2+ (Konsavage et al., 2008). In view of the impor-
tance of this loop,we further analyzed amutant carrying amutation in a
conserved residue of the loop (I146Awhich corresponds to I141 in HIV-
1 IN and T210 in PFV IN). Itwas initially assumed that themobility of the
loop would not be drastically altered by substituting an isoleucine with
a smaller residue such as alanine. Accordingly, the I146A IN displayed
strand transfer and disintegration activities similar to those of the WT
IN. The mutant also bound viral DNA with an efﬁciency similar to that
of theWT IN (Moreau et al., 2002). However, the I146A INwas less efﬁ-
cient than the WT IN in performing the 3′-processing reaction (Moreau
et al., 2002), the one-ended and two-ended concerted DNA integrations
(Fig. 3) and was present as a mix of monomers, dimers and tetramers
but with a slightly reduced ability to assemble as tetramers (Fig. 4). Fi-
nally, the decrease in one- and two-ended integration efﬁciencies
might be related to its reduced efﬁciency in performing 3′-processing.
The CCD has always been solved as a dimer in partial or entire IN
structures (Jaskolski et al., 2009) and was shown to be involved in di-
merization of the protein (Bujacz et al., 1995; Lubkowski et al., 1999).
Accordingly, the S85G mutation of the RAV-1 IN produced a severe de-
fect in multimerization (Andrake and Skalka, 1995). The relationship
between IN oligomerization and activities, especially two-ended DNA
integration activity, was further examined using two previously de-
scribed V79A and S85T mutant (Moreau et al., 2002). These mutations
have noticeable effects on IN properties: (i) the V79A and S85Tmutants
display a weak and strong reduction of DNA binding, respectively
(Moreau et al., 2002); this observation was also previously reported
for another S85 mutant (Katz et al., 1992); (ii) V79A and S85T INs dis-
played quite efﬁcient strand transfer and disintegration activities
(60–90% to that of the WT IN (Moreau et al., 2002)). V79A and S85T
were also able to carry out 3′-processing of the DNA but less efﬁciently
than the WT (efﬁciency is 30–60% that of the WT IN); furthermore, for
both mutants, one-ended DNA integration was strongly reduced
(Fig. 3); (iii) conversely, two-ended DNA integration remained efﬁcient
(47% and 80% that of the WT IN for V79A and S85T, respectively)
(Fig. 3A); (iv) mutation of the S85 residue drastically impaired dimer
and tetramer formation as revealed by cross-linking experiments
(Fig. 4) and size exclusion chromatography (data not shown and
(Andrake and Skalka, 1995)) while mutation of the V79 residue also re-
duced tetramer formation (although to a lesser extent than in S85T).
According to the crystal structure of this CCD (either as an isolated
domain or in the two domains RSV IN (CCD+CTD) (Bujacz et al.,
1995; Yang et al., 2000)) and in the light of the PFV IN intasomestructure (Maertens et al., 2010), these two residues are not involved
in contacts with another monomer (Table 1).
Assuming that two-ended concerted DNA integration may be per-
formed by a tetrameric form of IN (Bao et al., 2003; Faure et al., 2005;
Li and Craigie, 2005; Li et al., 2006), the results with mutant S85T, and
to a lesser extend with mutant V79A are striking. Based on our data,
we speculate that V79A and S85T might recover a correct fold by form-
ing high-order complexes in the presence of DNA. Interestingly, several
other data suggested protein conformational changes after DNA sub-
strate binding (Bao et al., 2003; Deprez et al., 2001; Vercammen et al.,
2002; Zhao et al., 2008), or cleavage (Gao et al., 2001) or after metal-
binding (Asante-Appiah and Skalka, 1997). A similar folding process
can be observed during the binding of intrinsically non-structured pro-
teins to their ligands (Dyson andWright, 2005). Thus,we used the cross-
link approach to analyze the oligomeric forms of these INs after binding
to different DNA substrates and showed that binding of DNA (viral or
not) induced V79A IN oligomerization (Fig. 5). Although the results
were less clear for S85T, they suggested that binding of viral DNA
could stimulate S85T dimers formation. Altogether, these data pointed
to a role of DNA in assembling catalytically active IN complexes. There-
fore, we hypothesize that binding of IN to DNAmay induce a conforma-
tional change whichwould allow the recruitment of other IN molecules
to form an active IN–DNA complex able to catalyze concerted integra-
tion of both ends. In that case, the β-turn between β2 and β3 strands
of RAV-1 IN may play a critical role in this DNA-induced assembly.
Conclusion
Several recent data point to the dynamic nature of the IN complex,
mainly modulated by linkers connecting the NTD, CCD and CTD
domains (Bojja et al., 2011; Michel et al., 2009; Zhao et al., 2008). Our
observations dissect further the dynamic nature of the IN by suggesting
a DNA-induced assembly of IN complexes involving a CCD internal
region (i.e. the β-turn between β2 and β3 strands). This part of IN
may constitute a new target for anti-viral drugs developments.
Materials and methods
Molecular modeling
Structural models of RAV-1 IN mutants were generated using the
homology-modeling web server Geno3D (Combet et al., 2002). As
RAV-1 IN shares 281 of its 286 amino acids with the Rous Sarcoma
Virus (RSV) IN, the CCD–CTD structure of RSV IN (PDB 1C0M (Yang et
al., 2000))was used as a template byGeno3D for substitutions targeting
the CCD of RAV-1 IN. Themodels obtainedwith Geno3Dwere displayed
and analyzed on a graphic station using the program PyMOL (DeLano,
2002).
Puriﬁcation of proteins
The RAV-1 IN coding sequences (wild type or mutants) were
cloned into the pET30a plasmid (Invitrogen) downstream of the six
histidine tag (Moreau et al., 2002). The INs were expressed in BL21
bacteria (Invitrogen), and puriﬁed as previously described (Moreau
et al., 2004).
DNAs
The pBSK-Zeo (target DNA) and pBSK-supF plasmids have been de-
scribed previously (Moreau et al., 2004). The U3–U5 donor DNA (D)
was ampliﬁed from pBSK-supF by PCR using pfu turbo polymerase (Pro-
mega) and the following primers: U3bis (AATGTAGTCTTATACGTT
GCCCGGATCCGG 3′) and U5bis (5′ AATGAAGCCTTCTGCTTTGAGCGTC-
GATTTTTG 3′) primers. The pU3–ΔU5 donor DNA (D2) was ampliﬁed
with primers SUP1 (5′ AACGTTGCCCGGATCCGGTC 3′) and SUP3 (5′
49J. Charmetant et al. / Virology 421 (2011) 42–50CGCCGAATTCTTTCTCAACG3′) (Moreau et al., 2009) The PCRproductwas
puriﬁed on a Qiaquick column (Qiagen) as described by the supplier. The
high-ﬁdelity pfu turbo DNA polymerase (Promega) that generates blunt-
ended PCR products was used. When necessary, donor DNA was radio-
labeled all along the molecule by including 8 μCi of dCTPα32P in the PCR
ampliﬁcation mixture (Moreau et al., 2004).
Integration reaction, gel analysis of the integration reaction and cloning
of coupled integration products
Integration reaction, gel analysis of the integration reaction and
cloning of coupled integration products were carried out as previously
described (Moreau et al., 2003, 2004) except that HMGI(Y)was omitted
from the reaction.
Protein–protein cross-linking
Wild type or mutant INs were treated with BS3 [bis (Disuccinimidyl
suberate)] (Pierce), as previously described (Moreau et al., 2003, 2004).
Covalently linked multimers were detected by separation on 8% SDS-
polyacrylamide gels and silver staining. In Fig. 5, IN (1.5 μg) was incu-
bated overnight with 0.6 pmol of DNA (i.e. 125 ng of D or D2 and/or
1.25 μg of target DNA) before being treated with BS3.
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